The efficacy and safety of romosozumab sequential therapy in postmenopausal women: A systematic review and
Tianfeng Li1,2, WeiJie Zheng1,2, Qiaoli Zhang1,2
1Department of Orthopedic Surgery, Nanping First Hospital Affiliated to Fujian Medical University, Nanping, China.
Background:
Recent guidelines increasingly recognize the importance of sequential therapy in osteoporosis management. However, optimal protocols involving the anabolic agent romosozumab require further elucidation. While previous meta-analyses support the use of osteoanabolic sequential therapy, uncertainties remain regarding the specific application of romosozumab in such regimens.
Objective:
This meta-analysis aims to provide detailed evidence on the efficacy and safety of romosozumab sequential therapy, specifically focusing on fracture prevention and bone mineral density (BMD) improvement in postmenopausal women with osteoporosis.
Data Sources And Methods:
A systematic literature search of PubMed, Embase, and Web of Science was conducted from January 2014 to December 2024. Two authors independently extracted data and assessed bias, with disagreements resolved by a third. Effect sizes were pooled using fixed- and random-effects models. The primary outcome was fracture incidence; secondary outcomes included BMD changes and adverse event rates.
Results:
Twelve randomized controlled trials were included. Sequential treatment with romosozumab followed by anti-resorptive agents (e.g., denosumab, alendronate) significantly reduced fracture incidence and increased BMD at the lumbar spine, total hip, and femoral neck compared to non-sequential therapy.
Conclusion:
Romosozumab sequential therapy may reduce fracture risk and improve BMD in postmenopausal women with osteoporosis, without a significant increase in short-term adverse events. However, evidence regarding new vertebral fractures and certain BMD outcomes remains limited in robustness, warranting further validation through high-quality, long-term studies.
Related Concept Videos
01:22Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
01:28Menopause
01:30Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
01:26Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:21Rheumatic Heart Disease III: Medical Management